---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-076715"
form_type: "8-K"
ticker: "SXTP"
cik: "0001946563"
company_name: "60 DEGREES PHARMACEUTICALS, INC."
filed_at: "2026-07-09T20:05:54+00:00"
generated_at: "2026-07-09T20:07:28.330268+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# 60 Degrees files SAP for tafenoquine babesiosis trial; interim analysis criteria set

## Summary
- 23 of 33 planned patients enrolled in randomized, placebo-controlled trial of tafenoquine for severe babesiosis (NCT0627370).
- Interim analysis at earlier of 10/30/26 or after 24 patients randomized and followed ≥50 days.
- Conditional power ≥80% for TTSCR with p≤0.02137 triggers early reporting; 50-80% triggers sample size reassessment (capped at 66 total).
- Company intends to apply for a National Priority Review Voucher if results support sNDA submission before Q1 2028.
- Sponsor and investigators remain blinded to interim analysis results if study continues.

## SEC filing metadata
- accession: 0001213900-26-076715
- form_type: 8-K
- ticker: SXTP
- cik: 0001946563
- company_name: 60 DEGREES PHARMACEUTICALS, INC.
- filed_at: 2026-07-09T20:05:54+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1946563/000121390026076715/0001213900-26-076715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1946563/000121390026076715/ea0297549-8k_60degrees.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-076715
- JSON: https://secwatch.observer/filing/0001213900-26-076715.json
- Plain text: https://secwatch.observer/filing/0001213900-26-076715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.